1h Free Analyst Time
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) pipeline Target constitutes close to 9 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report High Mobility Group Protein B1 - Drugs In Development, 2022, outlays comprehensive information on the High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - High mobility group box 1 protein also known as high-mobility group protein 1 (HMG-1) is a protein encoded by the HMGB1 gene.HMGB1 is secreted by immune cells like macrophages, monocytes and dendritic cells through leaderless secretory pathway. Activated macrophages and monocytes secrete HMGB1. The mechanism of inflammation and damage is binding to TLR4, which mediates HMGB1-dependent activation of macrophage cytokine release. Treatment includes antibodies that neutralize HMGB1 protects against damage and tissue injury during arthritis, colitis, ischemia, sepsis, endotoxemia, and systemic lupus erythematosus. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Infectious Disease, Central Nervous System, Oncology, Cardiovascular, Gastrointestinal, Dermatology and Musculoskeletal Disorders which include indications Cerebral Infarction (Brain Infarction), Non-Alcoholic Steatohepatitis (NASH), Parkinson's Disease, Sepsis, Traumatic Brain Injury, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Cardiomyopathy, Chronic Liver Disease, Dilated Cardiomyopathy, Epidermolysis Bullosa, Epilepsy, Hepatitis B, Hepatitis C, Influenzavirus A Infections, Ischemic Cardiomyopathy, Liver Cirrhosis, Liver Fibrosis, Osteoarthritis and Solid Tumor.
Furthermore, this report also reviews key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1)
- The report reviews High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- REPORT COVERAGE
- High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Overview
- High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Companies Involved in Therapeutics Development
- 180 Life Sciences Corp
- Chimerix Inc
- KaliVir Immunotherapeutics Inc
- Shionogi & Co Ltd
- TheraSource LLC
- High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Drug Profiles
- dociparstat sodium - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Drugs to Inhibit HMGB1 for Parkinson’s Disease - Drug Profile
- Product Description
- Mechanism Of Action
- HMGB1 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- JH-4 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibody to Inhibit HMGB1 for Influenza A Infections and Nervous System Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- Recombinant High Mobility Group Protein B1 Replacement for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- redasemtide trifluoroacetate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TSA-521 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- VET-4H1 - Drug Profile
- Product Description
- Mechanism Of Action
- High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Dormant Products
- High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) - Product Development Milestones
- Featured News & Press Releases
- Dec 13, 2021: SHIONOGI announces positive results from a Phase 2 clinical trial of the regeneration inducing medicine S-005151 (Redasemtide) in patients with acute ischemic stroke
- Feb 25, 2021: Chimerix reports promising topline results from first cohort of a randomized COVID-19 trial with DSTAT
- Feb 25, 2021: Chimerix reports promising topline results from first cohort of a randomized COVID-19 trial with DSTAT
- Apr 29, 2020: Chimerix announces initiation of a phase 2/3 study of DSTAT in acute lung injury for patients with severe COVID-19
- Dec 10, 2019: Chimerix presents updated results from phase 2 clinical trial of DSTAT in refractory myelodysplastic syndrome and acute myeloid leukemia at American Society of Hematology Annual Meeting
- Jun 04, 2018: Cantex Pharmaceuticals Announces That Clinical Trial Data For CX-01 In Refractory Acute Myeloid Leukemia And Myelodysplastic Syndrome Will Be Presented At The 2018 ASCO Annual Meeting
- Mar 12, 2018: Publication in Blood Advances Reports that the Combination of Cantex Pharmaceuticals CX-01 with Chemotherapy for the Treatment of Acute Myeloid Leukemia Showed Encouraging Complete Remission Rates and Rapid Platelet Count Recovery
- Jan 03, 2018: Cantex Pharmaceuticals Announces FDA Orphan Drug Designation Has Been Granted to CX-01 for Treatment of Acute Myeloid Leukemia
- Mar 02, 2016: New Patent Issued to Cantex Pharmaceuticals for Its Lead Product Candidate in the Treatment of Thrombocytopenia and Neutropenia
- Jun 01, 2015: Cantex Pharmaceuticals Announces Poster Presentation at ASCO 2015 Indicating Potential Efficacy of CX-01
- May 18, 2015: Cantex Pharmaceuticals Announces Efficacy and Safety Data from Study of CX-01 in AML to be Presented at 2015 ASCO Annual Meeting
- Feb 09, 2005: ParinGenix Gets FDA Approval of IND for PGX-100
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by 180 Life Sciences Corp, 2022
- Pipeline by Chimerix Inc, 2022
- Pipeline by KaliVir Immunotherapeutics Inc, 2022
- Pipeline by Shionogi & Co Ltd, 2022
- Pipeline by TheraSource LLC, 2022
- Dormant Products, 2022
List of Figures
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 180 Life Sciences Corp
- Chimerix Inc
- KaliVir Immunotherapeutics Inc
- Shionogi & Co Ltd
- TheraSource LLC
